Fig. 1

Tumor growth of CT26 tumor–bearing mice receiving IP doses of GITRL (mouse IgG2a) in (a) single doses or (b) repeated doses every other day for 9 doses. Data shown are representative of 2 repeat experiments. c Comparison of tumor growth in groups (n = 9) of CD8-depleted and nondepleted mice given IP doses of GITRL-FP or DTA-1. d Tumor growth rate of mice depleted of CD8 T-cells and treated with DTA-1 or GITRL-FP